MACDONALD LAURA ANN 4

4 · COGNEX CORP · Filed May 12, 2026

Research Summary

AI-generated summary of this filing

Updated May 12, 2026

Cognex (CGNX) VP Laura MacDonald Exercises Options and Sells Shares

What Happened
Laura Ann MacDonald, Vice President and Principal Accounting Officer of Cognex (CGNX), exercised multiple stock options between May 11–12, 2026 and immediately sold most of the resulting shares in open-market transactions. She acquired about 137,510 shares through option exercises (exercise costs ≈ $6,716,746) and sold ~139,722 shares for total proceeds of ≈ $9,282,195. The transactions produced roughly $2.57M in gross proceeds after exercise costs (before taxes/fees).

Key Details

Transaction dates: May 11–12, 2026. Sales prices were mostly $66.80 (May 11) and $65.56 (May 12). Exercise prices ranged from $33.04 to $56.44 across option grants.
Shares acquired by exercise: ~137,510 (total exercise cash paid ≈ $6.72M). Shares sold: ~139,722 (total proceeds ≈ $9.28M).
Some lines in the filing show $0.00 disposals for the options — these reflect conversion/cancellation of the derivative option instruments upon exercise.
Footnote F1: Certain securities are held by the reporting person’s child; the reporting person disclaims beneficial ownership except for pecuniary interest. Footnotes F2–F8 describe vesting schedules for the various option grants (grants from 2018–2025 with multi‑year vesting or cliff vesting as noted).
Filing: Reported period 2026-05-11 and filed 2026-05-12 (filed the next day, within the usual 2-business-day Form 4 window).

Context
These transactions are option exercises followed by immediate open-market sales (a common “exercise-and-sell” or cashless pattern) rather than outright purchases of new shares as a bullish signal. The filing is factual disclosure of insider activity; it does not state the insider’s motivation and should be considered informational for investors monitoring insider selling and option exercises.

Insider Transaction Report

Form 4

Period: 2026-05-11

COGNEX CORPCGNX

MACDONALD LAURA ANN

VP and PAO

Transactions

Exercise/Conversion
Common Stock
2026-05-11$33.04/sh+6,634$219,187→ 14,104 total
Sale
Common Stock
2026-05-11$66.80/sh−6,634$443,166→ 7,470 total
Exercise/Conversion
Common Stock
2026-05-11$39.44/sh+15,080$594,755→ 22,550 total
Sale
Common Stock
2026-05-11$66.80/sh−15,080$1,007,377→ 7,470 total
Exercise/Conversion
Common Stock
2026-05-11$47.21/sh+12,196$575,773→ 19,666 total
Sale
Common Stock
2026-05-11$66.80/sh−12,196$814,720→ 7,470 total
Exercise/Conversion
Common Stock
2026-05-11$50.94/sh+17,000$865,980→ 24,470 total
Sale
Common Stock
2026-05-11$66.80/sh−17,000$1,135,637→ 7,470 total
Exercise/Conversion
Common Stock
2026-05-11$51.49/sh+30,000$1,544,700→ 37,470 total
Sale
Common Stock
2026-05-11$66.80/sh−30,000$2,004,066→ 7,470 total
Exercise/Conversion
Common Stock
2026-05-11$56.44/sh+15,000$846,600→ 22,470 total
Sale
Common Stock
2026-05-11$66.80/sh−15,000$1,002,033→ 7,470 total
Sale
Common Stock
2026-05-11$66.80/sh−2,212$147,766→ 5,258 total
Exercise/Conversion
Common Stock
2026-05-12$47.21/sh+6,100$287,981→ 11,358 total
Sale
Common Stock
2026-05-12$65.56/sh−6,100$399,936→ 5,258 total
Exercise/Conversion
Common Stock
2026-05-12$48.28/sh+10,000$482,800→ 15,258 total
Sale
Common Stock
2026-05-12$65.56/sh−10,000$655,632→ 5,258 total
Exercise/Conversion
Common Stock
2026-05-12$50.94/sh+25,500$1,298,970→ 30,758 total
Sale
Common Stock
2026-05-12$65.56/sh−25,500$1,671,862→ 5,258 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F2]
2026-05-11−6,634→ 26,534 total
Exercise: $33.04From: 2026-02-18Exp: 2035-02-18→ Common Stock (6,634 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F3]
2026-05-11−15,080→ 22,618 total
Exercise: $39.44From: 2025-02-20Exp: 2034-02-20→ Common Stock (15,080 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F4]
2026-05-11−12,196→ 18,296 total
Exercise: $47.21From: 2024-02-21Exp: 2033-02-21→ Common Stock (12,196 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F4]
2026-05-12−6,100→ 12,196 total
Exercise: $47.21From: 2024-02-21Exp: 2033-02-21→ Common Stock (6,100 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F5]
2026-05-12−10,000→ 0 total
Exercise: $48.28From: 2022-05-01Exp: 2029-05-01→ Common Stock (10,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F6]
2026-05-11−17,000→ 25,500 total
Exercise: $50.94From: 2021-02-18Exp: 2030-02-18→ Common Stock (17,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F6]
2026-05-12−25,500→ 0 total
Exercise: $50.94From: 2021-02-18Exp: 2030-02-18→ Common Stock (25,500 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F7]
2026-05-11−30,000→ 0 total
Exercise: $51.49From: 2020-02-19Exp: 2029-02-19→ Common Stock (30,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F8]
2026-05-11−15,000→ 0 total
Exercise: $56.44From: 2019-02-20Exp: 2028-02-20→ Common Stock (15,000 underlying)

Holdings

Common Stock
[F1]
(indirect: By Children)
20
Non-Qualified Stock Option (right to buy)
Exercise: $57.09From: 2027-02-17Exp: 2036-02-17→ Common Stock (7,231 underlying)
7,231
Non-Qualified Stock Option (right to buy)
Exercise: $64.43From: 2023-02-22Exp: 2032-02-22→ Common Stock (23,891 underlying)
23,891
Non-Qualified Stock Option (right to buy)
Exercise: $90.50From: 2022-02-16Exp: 2031-02-16→ Common Stock (13,946 underlying)
13,946
Restricted Stock Unit
Exercise: $0.00From: 2025-02-20Exp: 2027-02-20→ Common Stock (3,169 underlying)
3,169
Restricted Stock Unit
Exercise: $0.00From: 2025-03-15Exp: 2027-03-15→ Common Stock (614 underlying)
614
Restricted Stock Unit
Exercise: $0.00From: 2026-02-18Exp: 2028-02-18→ Common Stock (9,685 underlying)
9,685
Restricted Stock Unit
Exercise: $0.00From: 2027-02-17Exp: 2029-02-17→ Common Stock (11,211 underlying)
11,211

Footnotes (8)

[F1]Held by reporting person's child. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
[F2]The options vest in five approximately equal annual installments on the first, second, third, fourth, and fifth anniversaries of the grant date (February 18, 2025).
[F3]The options vest in five approximately equal annual installments on the first, second, third, fourth, and fifth anniversaries of the grant date (February 20, 2024).
[F4]The options vest in five approximately equal annual installments on the first, second, third, fourth, and fifth anniversaries of the grant date (February 21, 2023).
[F5]The options vest 100% on the third anniversary of the grant date (May 1, 2019).
[F6]The options vest in five equal annual installments on the first, second, third, fourth, and fifth anniversaries of the grant date (February 18, 2020).
[F7]The options vest in five equal annual installments on the first, second, third, fourth, and fifth anniversaries of the grant date (February 19, 2019).
[F8]The options vest in five equal annual installments on the first, second, third, fourth, and fifth anniversaries of the grant date (February 20, 2018).

Signature

Laura A. MacDonald|2026-05-12

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT